CD274 and neoplasm: In the phase I/II NCT01693562 trial (Study 1108) of durvalumab 10 mg/kg q2w, 61 patients of the urothelial BCa cohort reached an ORR of 31.0%, ranging from 0% in PD-L1 negative (<25% on tumor or immune cells using the Ventana test) to 46.4% in PD-L1 positive (≥25%) patients.